KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares OutstandingShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Shares Issued (2016 - 2021)

Historic Shares Issued for Halozyme Therapeutics (HALO) over the last 12 years, with Q4 2021 value amounting to $4.3 million.

  • Halozyme Therapeutics' Shares Issued fell 6619.08% to $4.3 million in Q4 2021 from the same period last year, while for Dec 2021 it was $12.5 million, marking a year-over-year decrease of 8022.49%. This contributed to the annual value of $14.0 million for FY2022, which is 1207.72% up from last year.
  • According to the latest figures from Q4 2021, Halozyme Therapeutics' Shares Issued is $4.3 million, which was down 6619.08% from $4.6 million recorded in Q3 2021.
  • In the past 5 years, Halozyme Therapeutics' Shares Issued registered a high of $135.3 million during Q2 2017, and its lowest value of -$602000.0 during Q1 2021.
  • Over the past 5 years, Halozyme Therapeutics' median Shares Issued value was $4.2 million (recorded in 2021), while the average stood at $11.9 million.
  • In the last 5 years, Halozyme Therapeutics' Shares Issued crashed by 23789.47% in 2017 and then surged by 20640000.0% in 2018.
  • Halozyme Therapeutics' Shares Issued (Quarter) stood at -$1000.0 in 2017, then skyrocketed by 206400.0% to $2.1 million in 2018, then skyrocketed by 294.13% to $8.1 million in 2019, then soared by 56.78% to $12.7 million in 2020, then tumbled by 66.19% to $4.3 million in 2021.
  • Its Shares Issued was $4.3 million in Q4 2021, compared to $4.6 million in Q3 2021 and $4.2 million in Q2 2021.